Raras
Buscar doenças, sintomas, genes...
Doença de aglutininas frias
ORPHA:56425CID-10 · D59.1CID-11 · 3A20.1DOENÇA RARA

A doença das aglutininas frias é um tipo de anemia hemolítica autoimune definida pela presença de autoanticorpos frios (autoanticorpos ativos em temperaturas abaixo de 30°C).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A doença das aglutininas frias é um tipo de anemia hemolítica autoimune definida pela presença de autoanticorpos frios (autoanticorpos ativos em temperaturas abaixo de 30°C).

Pesquisas ativas
3 ensaios
23 total registrados no ClinicalTrials.gov
Publicações científicas
707 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D59.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
4 sintomas
🩸
Sangue
2 sintomas
🛡️
Imunológico
1 sintomas
💪
Músculos
1 sintomas
🫘
Rins
1 sintomas

+ 5 sintomas em outras categorias

Características mais comuns

90%prev.
Artralgia
Muito frequente (99-80%)
90%prev.
Autoimunidade
Muito frequente (99-80%)
90%prev.
Fraqueza muscular
Muito frequente (99-80%)
90%prev.
Fadiga
Muito frequente (99-80%)
90%prev.
Anemia hemolítica
Muito frequente (99-80%)
90%prev.
Palidez
Muito frequente (99-80%)
14sintomas
Muito frequente (6)
Ocasional (8)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 14 características clínicas mais associadas, ordenadas por frequência.

ArtralgiaArthralgia
Muito frequente (99-80%)90%
AutoimunidadeAutoimmunity
Muito frequente (99-80%)90%
Fraqueza muscularMuscle weakness
Muito frequente (99-80%)90%
FadigaFatigue
Muito frequente (99-80%)90%
Anemia hemolíticaHemolytic anemia
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico707PubMed
Últimos 10 anos200publicações
Pico202556 papers
Linha do tempo
2026Hoje · 2026🧪 2001Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 34
2Fase 27
1Fase 11
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 15 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de aglutininas frias

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

23 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
395 papers (10 anos)
#1

Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy.

Blood reviews2026 Mar 06

Autoimmune hemolytic anemias comprise warm AIHA (wAIHA), due to IgG autoantibodies reacting at body temperatures, and cold agglutinin disease (CAD), due to IgM reacting in cold and strongly activating complement. The diagnosis, based on the direct antiglobulin test (DAT), is sometimes difficult since the DAT is performed with various methods with different sensitivity and specificity. Novel investigation includes DAT by flow-cytometry that helps the diagnosis of DAT-negative forms and in-deep bone marrow examination that aims to understand AIHA pathogenesis. Therapy is different in wAIHA and CAD: in the former, steroids represent the first-line, followed by rituximab, splenectomy and immunosuppressors, while in the latter rituximab is recommended frontline, followed by rituximab plus chemotherapy or the complement inhibitor sutimlimab. Plasmacell-directed therapies (bortezomib and daratumumab) may be administered in refractory patients. Several new therapies are under investigation, including inhibitors of Bruton's and spleen tyrosine kinases, neonatal Fc receptor, and cytokines, and bi-specific monoclonal antibodies.

#2

Mutations in histone lysine methyltransferase genes are associated with autoimmune cytopenias: a single-center study.

Blood vessels, thrombosis &amp; hemostasis2026 Feb

Epigenetic dysregulation is increasingly recognized as a contributor to autoimmunity and autoimmune cytopenias (AIC). Histone lysine methyltransferases (MTs) are key regulators of gene expression through epigenetic modification. Germline MT mutations are associated with immunodeficiency syndromes such as Kabuki syndrome, which frequently co-occurs with AIC, while somatic KMT2D mutations have been reported in cold agglutinin disease. This study aimed to (1) determine the frequency of mutations in histone methyltransferase genes (KMT2D, KMT2A, KMT2C, and KDM6A) among patients with AIC, and (2) compare clinical, laboratory, and immunologic characteristics, as well as treatment responses, between patients with and without MT mutations. We retrospectively analyzed 534 patients who underwent comprehensive next-generation sequencing of bone marrow or peripheral blood; 80 had a diagnosis of AIC. Patients were categorized as MT-positive (MT⁺) or MT-negative (MT⁻) based on the presence of mutations in the specified genes. MT⁺ patients were significantly more likely to develop AIC compared with MT⁻ patients (25/90 vs 55/444). MT⁺ patients with AIC exhibited significantly lower serum immunoglobulin G levels, and those with autoimmune hemolytic anemia were more likely to demonstrate complement involvement on the direct antiglobulin test. MT variants identified in the AIC cohort were absent from the 1000 Genomes database and were predicted to be among the top 1% of the most deleterious variants based on Phred scores. These findings suggest that mutations in histone methyltransferase genes may play a role in the development of AIC. Prospective studies are warranted to validate these associations and to elucidate the epigenetic mechanisms underlying autoimmunity, which may ultimately support biomarker discovery and personalized approaches to disease management.

#3

Monoclonal Gammopathies of Thrombotic and Hemorrhagic Significance: Mapping into a classification schema.

Journal of thrombosis and haemostasis : JTH2026 Mar 16

Monoclonal gammopathies of clinical significance represent a heterogeneous spectrum of non-malignant disorders that may involve multiple organ systems or remain organ-restricted. These conditions are driven by circulating monoclonal proteins (MIg) secreted by small, often indolent, B-cell or plasma cell clones. Accumulating evidence has demonstrated that MIg may possess both thrombogenic and hemorrhagic potential, mediated through complex and multifactorial interactions with coagulation pathways, platelets, and the vascular endothelium. In this review, we critically appraise the spectrum of hemostatic complications associated with monoclonal gammopathies, encompassing entities such as amyloidosis, cold agglutinin disease, M-protein-associated antiphospholipid antibody syndrome, anti-PF4 antibody-mediated disorders, and thrombotic microangiopathies, among others. Given their substantial clinical burden and frequent under recognition, we propose that these MIg-driven hemostatic disorders be classified separately as monoclonal gammopathies of thrombotic/hemorrhagic significance (MGTHS) encompassing both thrombotic and hemorrhagic subtypes. We additionally outline a proposed diagnostic approach emphasizing systematic evaluation for alternative etiologies, characterization of the monoclonal protein, and assessment for clinical, laboratory, and treatment-response features supporting pathogenic attribution. Establishing such a nosological framework highlights the clinical importance of these conditions and underscores the need for systematic recognition, diagnostic evaluation, and multidisciplinary management of these often overlooked but clinically consequential entities.

#4

Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.

The American journal of case reports2026 Mar 07

BACKGROUND Cryoglobulinemia is a rare disease with a prevalence of <5 cases per 10 000. In many cases there is significant diagnostic delay, leading to years of morbidity. There are no randomized trials on non-infectious type II cryoglobulinemia, and choice of therapy is based on clinical expertise and observational data. Therapy based on the monoclonal anti-CD20 antibody rituximab in combination with glucocorticosteroids is the preferred choice in many centers. This strategy induces clinical remission in two-thirds of patients. However, one-third of the initially-responding patients experience relapse within the first year. As such, many patients will not achieve sustained remission. CASE REPORT We describe the clinical course of 2 patients with non-infectious type II cryoglobulinemia. They were initially treated according to standard clinical practice, without lasting symptom relief. A novel treatment strategy was attempted, targeting the underlying B-cell clone responsible for the production of disease-inducing monoclonal immunoglobulins. These protocols, initially developed for treatment of chronic cold agglutinin disease, contain rituximab in combination with fludarabine or bendamustine. Sustained clinical, immunological, and hematological remissions were achieved in both patients, and the treatment was well tolerated with no need for hospitalization or other supportive measures. CONCLUSIONS Treating patients with type II cryoglobulinemia using chemo-immune therapy in the same regimens as used in cold agglutinin disease could be considered as a therapeutic option. Based on our observations in the 2 patients described in this case series, this approach seems feasible and well tolerated. Deep sustained remissions may be possible.

#5

Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.

Frontiers in immunology2026

Cold agglutinin disease is an autoimmune condition characterised by expression of self-reactive antibodies to I/i carbohydrate blood group antigens (polymers of N-acetyllactosamine or 'LacNAc' units) resulting in anaemia through the agglutination and complement-mediated destruction of red blood cells. This antibody response is dominated by antibodies of the human IGHV4-34 germline, which display a unique hydrophobic patch formed by germline-encoded tryptophan and tyrosine residues at positions 7 and 25 within framework 1 (FR1). Although the requirement for conservation of this FR1 patch for binding to the I/i carbohydrate antigen has been well established, structural insights regarding the mechanistic role of the FR1 patch have remained elusive. Intriguingly, recent papers describing IGHV4-34 antibodies bound to the glycan-adorned surface of the HIV envelope glycoprotein shed light on the utility of this FR1 surface. Rather than indirectly shaping the conformation of the conventional antigen binding site as previously proposed, the structures reveal direct interfaces between the hydrophobic FR1 patch and high mannose glycans projected by HIV. Given the stereochemical similarities between these glycans and LacNAc, these structures suggest how I/i self-antigen glycans might be similarly engaged by IGHV4-34 antibodies in a framework-centric non-CDR mode and provide a rationale for the preservation of this otherwise self-reactive antibody germline.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC434 artigos no totalmostrando 198

2026

Monoclonal Gammopathies of Thrombotic and Hemorrhagic Significance: Mapping into a classification schema.

Journal of thrombosis and haemostasis : JTH
2026

Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy.

Blood reviews
2026

Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.

The American journal of case reports
2026

Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.

Frontiers in immunology
2026

[Pure red cell aplasia in a patient with cold agglutinin disease-associated lymphoproliferative disorder].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2026

A Cold Case: Cold Agglutinin Disease Complicating Stem Cell Transplant.

Case reports in transplantation
2026

Monoclonal gammopathies of cutaneous significance: A nomenclature and pathophysiology-based classification.

Journal of the American Academy of Dermatology
2026

Sutimlimab for Relapsed Cold Agglutinin Disease: Real-Life Evidence of Sustained Response With Extended-Interval Dosing.

European journal of haematology
2025

Double Agglutination Observed in Mycoplasma-Associated Kawasaki Disease: Pathophysiological Insights and Considerations for Treatment Strategy.

Cureus
2026

A case of concurrent cold agglutinin disease and C3 glomerulonephritis requiring differentiation from other iatrogenic immunodeficiency-associated lymphoproliferative disorder in a patient with rheumatoid arthritis and Sjögren's disease.

Immunological medicine
2026

Their Blood Ran Cold: A Case Series on Cold Agglutinin Disease.

QJM : monthly journal of the Association of Physicians
2025

[Advances in the treatment of cold agglutinin disease and their impact on quality of life].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2026

Phagocytosis of Lymphocytes and Erythrocytes by B-Cell Lymphoma in a Patient With a Clinical Suspicion of Pure Red Cell Aplasia.

Clinical case reports
2025

Paroxysmal Cold Hemoglobinuria Associated With Monoclonal B-Cell Lymphocytosis in an Elderly Patient: A Report of a Rare Case.

Cureus
2025

Autoimmune Hemolytic Anemia in Non-Hodgkin's Lymphoma: Pathogenesis, Diagnosis, and Management.

Nigerian journal of clinical practice
2026

Mutations in histone lysine methyltransferase genes are associated with autoimmune cytopenias: a single-center study.

Blood vessels, thrombosis &amp; hemostasis
2026

Sutimlimab in Patients With Cold Agglutinin Disease (CAD): Results From a Managed Access Program.

European journal of haematology
2025

Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody.

Proceedings of the National Academy of Sciences of the United States of America
2026

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial.

American journal of hematology
2025

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program
2025

Management of autoimmune hemolytic anemia.

Hematology. American Society of Hematology. Education Program
2025

Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells.

bioRxiv : the preprint server for biology
2025

Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders.

Journal of blood medicine
2025

Durable responses and favorable cost-effectiveness of rituximab-based chemoimmunotherapy for primary cold agglutinin disease.

Blood research
2025

Case Report: Coexisting cold agglutinin disease and acquired hemophilia A: a rituximab-responsive dual autoimmune disorder.

Frontiers in medicine
2026

Complement-targeting therapies in hemolytic diseases.

Current opinion in immunology
2025

A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.

Diagnostics (Basel, Switzerland)
2025

Cerebral venous sinus thrombosis with cold agglutinin disease in summer: illustrative case.

Journal of neurosurgery. Case lessons
2025

Partial arch replacement for type A aortic dissection with cold agglutinin disease after sutimlimab.

Journal of cardiology cases
2025

Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia.

British journal of haematology
2025

Iptacopan for cold agglutinin disease: a case report with literature review.

Frontiers in immunology
2025

Refractory cold autoimmune hemolytic anemia as initial presentation of gastric B cell lymphoma: a case report.

Journal of medical case reports
2025

Cold Agglutinin Syndrome as the Initial Presentation of Acute Myeloid Leukemia: A Case Report.

Clinical case reports
2025

Rosai-Dorfman-Destombes disease in an elderly man. A case of necrosis in the lymph node.

American journal of blood research
2025

Unifying serological testing for cold agglutinins.

Vox sanguinis
2025

Cold Agglutinin Disease in the Setting of Pancreatic Adenocarcinoma.

European journal of case reports in internal medicine
2025

In response: Approach to autologous stem cell harvesting and transplantation in patients with cold-agglutinin disease or cryoglobulins.

Transfusion
2025

A unique case of red blood cell agglutination reaction on glass surface in otherwise normal sample.

Asian journal of transfusion science
2025

Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions.

Frontiers in immunology
2025

A Case of Primary Cold Agglutinin-Mediated Hemolytic Anemia Successfully Treated with Steroids.

Cureus
2025

[Treatment strategies for autoimmune hemolytic anemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2025

The Role of Cold Agglutinins Screening in Cardiac Surgery: Necessity or Redundancy?

Sisli Etfal Hastanesi tip bulteni
2025

A Case of Cold Agglutinin Disease With Transformation to High-Grade Lymphoma During Sutimlimab Treatment.

Cureus
2025

Successful treatment for distal-arch aortic aneurysm in a cold agglutinin-positive patient via physician-modified thoracic endovascular aortic repair: a case report.

General thoracic and cardiovascular surgery cases
2025

A Rare Case of Cold Antibody-Mediated Autoimmune Haemolytic Anaemia in Early Systemic Lupus Erythematosus.

Cureus
2025

[Cold agglutinin disease (CAD)].

Innere Medizin (Heidelberg, Germany)
2025

[Anterolateral Partial Sternotomy as an Effective Approach for Open Repair After Debranching Thoracic Endovascular Aortic Repair in Aortic Arch Aneurysm].

Kyobu geka. The Japanese journal of thoracic surgery
2025

Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study.

EJHaem
2025

A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer.

International cancer conference journal
2025

Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023.

PloS one
2025

Concurrence of mixed cryoglobulinaemia and cold agglutinin disease, and the putative role for a stereotyped immunoglobulin light chain.

British journal of haematology
2025

DRESS Syndrome with Cold Agglutinins: An Unusual Immune Response to Anticonvulsants.

Current drug safety
2025

Anesthetic Management During Total Abdominal Hysterectomy in a Patient With Cold Agglutinin Disease: A Case Report.

Cureus
2025

Anesthesia for Urgent Gastroscopy in Cold Agglutinin Disease: A Case Report and Literature Review.

Cureus
2025

A middle-aged woman with the initial symptom of acrocyanosis diagnosed with cold agglutinin disease: A case report.

SAGE open medical case reports
2025

Intervascular Large B-cell Lymphoma with Severe Anemia and a High-titer of Cold Agglutinin.

Internal medicine (Tokyo, Japan)
2025

Ambulatory total knee arthroplasty in a patient with cold agglutinin disease.

Canadian journal of anaesthesia = Journal canadien d'anesthesie
2025

[Clinical and Laboratory Characteristics of Cold Agglutinin Disease Patients with Positive Results of Acidified-Serum Lysis Test].

Zhongguo shi yan xue ye xue za zhi
2025

Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses.

Clinical pharmacology and therapeutics
2025

Spinal Anesthesia in a Patient With Cold Agglutinin Disease Presenting for Total Knee Arthroplasty in a Community Hospital Setting.

Cureus
2025

Cold agglutinin disease coexisting with left main coronary artery involvement and ventricular dysfunction - a challenging triad.

Indian journal of thoracic and cardiovascular surgery
2025

Treatment of autoimmune hemolytic anemia: novel and investigational approaches.

Minerva medica
2025

A rare case of gastrointestinal diffuse large B cell lymphoma with cold agglutinin disease presentation.

The Kaohsiung journal of medical sciences
2025

Intracapillary Monoclonal IgM Deposition Concomitant With Cold Agglutinin Disease.

Kidney medicine
2025

Abdominal Aortic Aneurysm with Primary Cold Agglutinin Disease Treated with Endovascular Aortic Repair.

Annals of vascular diseases
2025

Approach to autologous stem cell transplantation in a patient with severe cold agglutinin disease, a case report.

Transfusion
2025

Intraoperative vascular anastomosis occlusion due to cold agglutinin disease during brain surgery: a case report.

JA clinical reports
2024

Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.

Frontiers in medicine
2024

Severe mycoplasma pneumoniae pneumonia combined with cold agglutinin disease and pulmonary embolism in childhood: A case report and review of the literature.

African journal of reproductive health
2024

Breast Adenocarcinoma and Cold Agglutinin Disease: A Paraneoplastic Syndrome.

Cureus
2024

Successful rituximab treatment in a seronegative rheumatoid arthritis patient with concurrent cold agglutinin syndrome and immune thrombocytopenia.

Rheumatology international
2024

Stay Away From the Cold: An Unusual Case of Cold Agglutinin Disease Presenting as Recurrent Transient Ischemic Attacks.

Cureus
2024

Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.

Blood advances
2024

Anesthesia Management of Cold Agglutinin Disease in a Pregnant Patient: A Case Report.

Clinical case reports
2024

Navigating cold agglutinin-induced hemolytic anemia in developing countries: A case report and literature review.

SAGE open medical case reports
2024

Autoimmune haemolytic anaemias.

Nature reviews. Disease primers
2025

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.

Blood
2024

Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.

American journal of hematology
2024

Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease.

International journal of hematology
2024

The Vital Role of Immunohematology in Diagnosing Paroxysmal Cold Hemoglobinuria: A Clinical Case Report.

Cureus
2024

Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
2024

[Current recommendations for the diagnosis and treatment of autoimmune hemolytic anemia based on etiology and pathology].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2024

Sutimlimab for Cold Agglutinin Disease.

Journal of the advanced practitioner in oncology
2024

Cold Agglutinin Disease: A Rare Paraneoplastic Manifestation of a Thyroid Malignancy.

Cureus
2024

[The treatment strategies of autoimmune hemolytic anemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2024

[Cold agglutinin syndrome associated with infectious mononucleosis: A case report].

Revista medica del Instituto Mexicano del Seguro Social
2024

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.

EClinicalMedicine
2024

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

EClinicalMedicine
2024

Concurrent existence of cold agglutinin disease and ANCA-associated vasculitis with fulminant pulmonary-renal syndrome poses significant treatment challenges.

BMJ case reports
2025

Efficacy of sutimlimab for cold agglutinin disease in a patient on chronic hemodialysis.

CEN case reports
2024

[Cold agglutinin disease: pathology, diagnosis, and treatment].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2024

The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms.

Expert review of hematology
2024

Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.

Current oncology reports
2024

Obinutuzumab for the Treatment of Cold Agglutinin Disease: A Case Report.

Turkish journal of haematology : official journal of Turkish Society of Haematology
2024

The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease.

Expert review of hematology
2023

A Case of Renal Iron Overload Associated with Cold Agglutinin Disease Successfully Managed by Rituximab.

Clinical hematology international
2024

Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890-5897.

Blood advances
2025

New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications.

International journal of hematology
2024

Cost-effectiveness of sutimlimab in cold agglutinin disease.

American journal of hematology
2024

[Sutimlimab for cold agglutinin disease, a newcomer among complement inhibitors in immunohematology].

La Revue de medecine interne
2025

Successful Management of Total Plasma Exchange for Hemolytic Cold Agglutinin Disease.

Internal medicine (Tokyo, Japan)
2024

Successful treatment of concurrent cold agglutinin disease and myelodysplastic syndrome.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
2024

When you think you should transfuse…don't!

Laboratory medicine
2024

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.

Blood advances
2024

COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.

American journal of hematology
2024

A Rare Case Presentation: EBV-related Cold Agglutinin Disease and Venous Thrombosis.

The Pediatric infectious disease journal
2024

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes.

Journal of clinical medicine research
2023

Clinical and laboratory characteristics of patients with cold agglutinin disease: A retrospective analysis at a tertiary medical center.

Asian journal of transfusion science
2023

Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease.

Journal of clinical and experimental hematopathology : JCEH
2024

Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease.

Clinical and experimental immunology
2023

Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights.

Journal of cardiovascular development and disease
2023

The Importance of Early Suspicion for Cold Autoimmune Hemolytic Anemia.

Cureus
2023

[Sjögren's syndrome combined with cold agglutinin disease: A case report].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
2023

Cold Agglutinin Disease in a Rhesus Macaque (Macaca mulatta).

Comparative medicine
2024

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.

Blood
2023

Novel pharmacotherapy for drug-induced immune hemolytic anemia.

Expert opinion on pharmacotherapy
2024

Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis.

Blood advances
2023

Cytokine polymorphisms in patients with autoimmune hemolytic anemia.

Frontiers in immunology
2024

Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone.

Leukemia &amp; lymphoma
2024

Organizing Pneumonia in a Case of Cold Agglutinin Disease with Pulmonary Thrombosis.

Internal medicine (Tokyo, Japan)
2024

Cold agglutinin disease and cryoglobulinaemia: A frequent coexistence with clinical impact.

British journal of haematology
2023

Cold agglutinin disease in childhood: a case series with review of literature.

Recenti progressi in medicina
2023

Antibody based therapeutics for autoimmune hemolytic anemia.

Expert opinion on biological therapy
2023

Total arch replacement for an aortic arch aneurysm with cold agglutinin disease after rituximab and plasmapheresis.

Journal of cardiothoracic surgery
2023

Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps.

Frontiers in immunology
2023

[Novel therapeutic agents for hemolytic anemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2023

A case of cold agglutinin disease in a bottlenose dolphin (Tursiops truncatus).

The Journal of veterinary medical science
2023

Systemic Lupus Erythematosus and Antiphospholipid Syndrome Accompanied by Mixed-Type Autoimmune Hemolytic Anemia.

Case reports in rheumatology
2024

Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.

British journal of haematology
2023

Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature.

Hematology (Amsterdam, Netherlands)
2023

Cold agglutinin disease: A case report with atypical clinical findings.

SAGE open medical case reports
2023

Cold Agglutinins Causing Intracoronary Hemagglutination During Premature Ventricular Contraction Ablation Requiring Thrombectomy and Venoarterial Extracorporeal Membrane Oxygenation.

Journal of cardiothoracic and vascular anesthesia
2023

A Rare Case of Cold Agglutinin Syndrome Associated With Legionella Pneumonia.

Cureus
2023

Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.

Blood advances
2023

Low-grade B cell lymphoma in the perirenal space of the left kidney associated with high titer cold agglutinin disease.

American journal of blood research
2023

[Novel anti-complement therapeutics for hemolytic anemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2023

Hemolytic Anemia in the Setting of Atypical Pneumonia: A Case of Cold Agglutinin Disease.

Cureus
2023

Molecular pharmacology in complement-mediated hemolytic disorders.

European journal of haematology
2023

Complement-directed therapy for cold agglutinin disease: sutimlimab.

Expert review of hematology
2023

The Histopathology of Cold Agglutinin Disease-Associated B-Cell Lymphoproliferative Disease.

American journal of clinical pathology
2023

A Case Report of Cold Agglutinin Disease, Severe B12 Deficiency, and Pernicious Anemia: A Deadly Coincidence.

Cureus
2023

Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.

American journal of hematology
2023

Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias.

Expert review of hematology
2023

Primary cold agglutinin disease: a recently recognised diagnostic entity in WHO and ICC.

Histopathology
2023

The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?

Frontiers in immunology
2023

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease.

The Journal of pharmacology and experimental therapeutics
2023

Sutimlimab for the Treatment of Cold Agglutinin Disease.

HemaSphere
2023

Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.

Clinical immunology (Orlando, Fla.)
2023

A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D.

International journal of hematology
2023

Monoclonal antibodies for treatment of cold agglutinin disease.

Expert opinion on biological therapy
2023

Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD-SIQ).

European journal of haematology
2023

Uncovering the Unusual: A Case of Mixed Connective Tissue Disease With Rare Presentation, Atypical Complications, and Therapeutic Dilemmas.

Cureus
2023

IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders.

Haematologica
2023

Three different pathways of IgM-antibody-dependent hemolysis are mainly regulated by complement.

Frontiers in immunology
2023

Spurious macrocytic anaemia in a patient with systemic lupus erythematosus: cold agglutinin disease.

Clinical rheumatology
2022

Rise of the planet of rare anemias: An update on emerging treatment strategies.

Frontiers in medicine
2023

Daratumumab as a novel treatment option in refractory ITP.

Blood cells, molecules &amp; diseases
2023

Neutrophilic erythrophagocytosis in myelodysplastic syndrome and cold agglutinin disease co-occurrence.

Clinical case reports
2023

Successful Management of Refractory Autoimmune Hemolytic Anemia with Cold Agglutinin Disease with Splenectomy: A Case Report with Review of Literature.

The Kobe journal of medical sciences
2022

Perioperative Management of a Patient With Severe Cold Agglutinin Disease Undergoing Total Hip Arthroplasty With a Cemented Stem: A Case Report.

A&amp;A practice
2022

Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States.

PloS one
2023

An atypical case of refractory passenger lymphocyte syndrome after renal transplantation.

Nefrologia
2022

Cold AIHA and the best treatment strategies.

Hematology. American Society of Hematology. Education Program
2023

Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.

The Annals of pharmacotherapy
2024

Incidentally discovered cold hemagglutinins within autologous blood bag and cardioplegia line in a patient with a recent history of COVID-19 undergoing coronary artery surgery.

Perfusion
2022

An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database.

Journal of managed care &amp; specialty pharmacy
2022

Bilateral retinal vasculitis associated with cold agglutinin disease treated with obinutuzumab and infliximab.

American journal of ophthalmology case reports
2023

Plasma cell neoplasms and related entities-evolution in diagnosis and classification.

Virchows Archiv : an international journal of pathology
2023

Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.

European journal of haematology
2023

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease.

Blood advances
2023

Chronic cold agglutinin disease after a third COVID-19 mRNA vaccination.

International journal of hematology
2022

Complement C1s as a diagnostic marker and therapeutic target: Progress and propective.

Frontiers in immunology
2022

Dual arterial thrombosis: A diagnostic enigma.

Annals of African medicine
2022

[Advances in understanding the pathogenesis and treatment of autoimmune hemolytic anemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2022

Cryoglobulins and cold agglutinins for hand arm vibration syndrome.

Occupational medicine (Oxford, England)
2022

Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?

Transfusion medicine reviews
2022

Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.

Blood and lymphatic cancer : targets and therapy
2022

Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.

Annals of hematology
2023

Practical therapy for primary autoimmune hemolytic anemia in adults.

Clinical and experimental medicine
2022

[Recent progress in the diagnosis and treatment of cold agglutinin disease].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2022

How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease?

Transfusion
2022

Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?

Immunotherapy
2022

The Burden of Cold Agglutinin Disease on Patients' Daily Life: Web-Based Cross-sectional Survey of 50 American Patients.

JMIR formative research
2022

The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19.

Immunobiology
2022

[Thrombotic risk in autoimmune hemolytic anemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2022

Novel Insights into Factor D Inhibition.

International journal of molecular sciences
2022

IgM monoclonal gammopathies of clinical significance: diagnosis and management.

Haematologica
2022

Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia.

Cureus
2022

Heavy chain/light chain assay is a useful biomarker for diagnosis and management of patients with cold agglutinin disease.

British journal of haematology
2022

Autoimmune hemolytic anemia: causes and consequences.

Expert review of clinical immunology
2022

[Splenic lymphoma, diagnosis and treatment].

La Revue de medecine interne
2022

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

Blood
2022

Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.

British journal of haematology
2022

Development of New Drugs for Autoimmune Hemolytic Anemia.

Pharmaceutics
2022

Microvascular free tissue transfer in the setting of cold agglutinin disease.

Microsurgery
2022

Bone marrow and peripheral blood involvement of relapsed diffuse large B-cell lymphoma after prior cold agglutinin disease.

International journal of laboratory hematology
2022

Mortality in cold agglutinin disease shows seasonal pattern.

Transfusion
2022

Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab.

BMJ case reports
Ver todos os 434 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de aglutininas frias.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de aglutininas frias

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy.
    Blood reviews· 2026· PMID 41813558mais citado
  2. Mutations in histone lysine methyltransferase genes are associated with autoimmune cytopenias: a single-center study.
    Blood vessels, thrombosis &amp; hemostasis· 2026· PMID 41438733mais citado
  3. Monoclonal Gammopathies of Thrombotic and Hemorrhagic Significance: Mapping into a classification schema.
    Journal of thrombosis and haemostasis : JTH· 2026· PMID 41850491mais citado
  4. Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.
    The American journal of case reports· 2026· PMID 41792990mais citado
  5. Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.
    Frontiers in immunology· 2026· PMID 41789059mais citado
  6. Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.
    Am J Hematol· 2026· PMID 41991255recente
  7. Case Report: Refractory cold agglutinin disease with hypersplenism: efficacy of splenectomy in a patient treated with sutimlimab.
    Front Immunol· 2026· PMID 41983131recente
  8. Clinicopathological features of primary cold agglutinin disease in the Japanese population: Heterogeneous characteristics and diagnostic challenges.
    J Clin Exp Hematop· 2026· PMID 41922224recente
  9. Sutimlimab vs B-Cell-Targeted Therapy in Cold Agglutinin Disease: Which Is the Optimal Approach?
    Blood· 2026· PMID 41911068recente
  10. Severe Intravascular Hemolysis and Acute Kidney Injury Triggered by Mycoplasma-Associated Cold Agglutinin Disease: A Case Report.
    Clin Med Insights Case Rep· 2026· PMID 41884193recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:56425(Orphanet)
  2. MONDO:0018922(MONDO)
  3. GARD:6130(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Q3961632(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de aglutininas frias
Compêndio · Raras BR

Doença de aglutininas frias

ORPHA:56425 · MONDO:0018922
Prevalência
1-9 / 1 000 000
Herança
Multigenic/multifactorial
CID-10
D59.1 · Outras anemias hemolíticas auto-imunes
CID-11
Ensaios
3 ativos
Início
Adult
Prevalência
0.0 (Europe)
MedGen
UMLS
C0175816
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades